ELISHA Technology Measures Cancer and Stroke Markers..

06/Jun/2006

The ELISHA Project has successfully produced an immunosensor platform that has been shown to measure prostate cancer biomarkers in a simple, rapid assay format. The flexibility of the platform has also allowed the detection of two trauma biomarkers that can be used for confirmation of stoke, ischaemia or heart attack. The platform is available for commercial exploitation. Please contact us for more details.


The ELISHA project is designed to produce simple, rapid immunosensors that can detect antibody - antigen binding at the levels of standard ELISA (Enzyme Linked Immuno Sorbant Assays), which are one of the most common test systems used commercially.

The concept is to reduce immunoassays to a simple directly readable immunosensor, by using an electronic reader linked to different immunostrips to allow a multitude of analytes to be specifically detected in minutes. The concept is analagous to the blood glucose biosensor, except antibodies are used as the sensitive and selective reagent.

The project has already demonstrated detection of PSA, S-100 protein, NSE, Haemoglobin, Myoglobin and fluorquinoline antibiotics (Ciprofloxacin). Specificity of immunostrips is directly dictated by which antibody is used and therefore the ELISHA platform is extremely versatile and will be able to be used in many different areas.

The ELISHA website is www.immunosensors.com
The active link can be found under the Links menu on the top bar.



Back